Atorvastatin in the Treatment of Dyslipidemic Patients with Very High Cardiovascular Risk and Nonalcoholic Fatty Liver Disease
| Autor: | Antoniu Petris, Dan Iliescu, Alexandru Dan Costache, Irina Garleanu, Amalia Timpau, Adriana Ion, Razan Al Namat, Radu Miftode, Delia Melania Popa, Dan Tesloianu, Irina Iuliana Costache, Viviana Aursulesei |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
business.industry Materials Science (miscellaneous) Process Chemistry and Technology Atorvastatin General Engineering nutritional and metabolic diseases General Chemistry General Medicine medicine.disease Gastroenterology General Biochemistry Genetics and Molecular Biology Internal medicine Nonalcoholic fatty liver disease Materials Chemistry medicine lipids (amino acids peptides and proteins) General Pharmacology Toxicology and Pharmaceutics business medicine.drug |
| Zdroj: | Revista de Chimie. 70:2159-2161 |
| ISSN: | 2668-8212 0034-7752 |
| Popis: | Nonalcoholic fatty liver disease (NAFLD) is defined as the presence of hepatic fat accumulation after ruling out other causes of hepatic steatosis. The aim of the study is to identify the role of statin therapy in dyslipidemic patients with very high cardiovascular risk and NAFLD in achieving low density lipoprotein (LDL) cholesterol targets while also evaluating the changes in liver enzymes levels. This prospective study included 140 patients with NAFLD, hyperlipidemia and elevated cardiovascular risk. Serum lipids were assessed and liver function tests were performed at baseline and at 6 months follow up in 10 mg/ 20 mg daily atorvastatin treatment schedule. The results showed that total cholesterol, LDL cholesterol and triglycerides were significantly reduced at 6 months follow-up, while high density lipoprotein (HDL) cholesterol has not undergone important changes. Statin treatment significantly improved alanine aminotransferase serum levels, whereas aspartate aminotransferase levels were not significantly reduced between baseline and follow-up. Although statin therapy appears to be safe and effective for use in patients with NAFLD, an insufficient treatment is commonly observed in clinical practice, in order to avoid liver damage . NAFLD is not only a major cause of liver related morbidity and mortality, but also an independent cardiovascular risk factor, with cardiovascular mortality being the most important cause of death. Therefore, detecting and modifying risk factors without impairing liver function is desirable. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|